ArticleRSC advances2020
Design and fabrication of a microfluidic chip to detect tumor markers.
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 11 citations in OpenAlex.
- Advances in Non-Electrochemical Sensing of Human Sweat Biomarkers: From Sweat Sampling to Signal Reading.Biosensors · 2023Review
- Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.Journal of pharmaceutical analysis · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A microfluidic chip based on capillary infiltration was designed to detect tumor markers. Serum samples flowed along a microchannel that used capillary force to drive sample injection, biochemical reactions and waste liquid collection. This permitted us to realize rapid qualitative detection of tumor markers and other biological molecules. The chip integrated a number of microfluidic functions including blood plasma separation, microvalve operation, and antibody immobilization. Using antigen-antibody reaction principles, the chip provided highly selective and sensitive detection of markers. Combining a microfluidic chip with immunoassays not only improved the antigen-antibody reaction speed, but also reduced the consumption of samples and reagents. The experimental results showed that the chip can achieve separation of trace whole blood, control of sample flow rate, and detection of alpha fetoprotein, thus providing preliminary verification of its feasibility and potential for clinical use. In summary, in this paper a cheap, mass-produced, and portable microfluidic chip for cancer detection, which has good prospects for practical use during disease diagnosis and screening is reported.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.